Antimicrobial Therapeutics Market Size

Global Antimicrobial Therapeutics Market Overview

The Antimicrobial Therapeutics Market Size was valued at USD 95.6 Billion in 2022 and is projected to grow from USD 100.7 Billion in 2023 to USD 152.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.30% during the forecast period (2024 - 2032). Recent drug approvals, a strong pipeline, government agency initiatives, and growing knowledge of microbial diseases all contribute to the pharmaceutical industry's success, are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Antimicrobial Therapeutics Market Trends

• Rising trend of cycling is driving the market growth

The primary drivers of the market are the increased prevalence of infectious diseases and favorable governmental regulations. Additionally, a rise in infections with antibiotic resistance brought on by improper or excessive use of antibiotics is anticipated to change prescription trends for innovative medicines to treat bacterial infections. The CDC estimates that there are over 2.8 million antibiotic-resistant illnesses in the United States. In affluent nations, the resistance rate for diseases including Enterobacteriaceae, P. aeruginosa, and K. pneumoniae is considerable, averaging 40%.

Over the projected period, the market is anticipated to be driven by pharmaceutical firms' increased efforts in the discovery of innovative treatments to treat infectious disorders. Around 41 promising compounds were being researched in December 2019 for the treatment of dangerous bacterial infections, according to Pew Charitable Trust. 17 of these 41 experimental medications are either in the third stage of clinical trials or have submitted an NDA for approval, and it is anticipated that they will be on sale within the projection period. The U.S. FDA approved four new antibiotic medications in the second half of 2019. Additionally, it is hoped that favorable government legislation, such as the GAIN Act and REVAMP Act, may hasten the clearance process globally. Over the course of the projected period, the introduction of novel antibiotic medications is anticipated to promote market expansion.

Due to the rise in infectious disease cases, there is a noticeable increase in the demand for antibiotics. Another factor driving the market's expansion is the high prevalence of infectious disorders like lower respiratory infections, pneumonia, malaria, and tuberculosis. Government and non-government organizations are being forced to invest in R&D programs and advance the creation of novel antibiotics and helpful regulatory rules in order to speed up the approval procedure and research financing. For instance, BARDA has provided support to numerous businesses in conjunction with the government to help in the development of novel treatments for infectious diseases. Thus, driving the Antimicrobial Therapeutics market revenue.

Antimicrobial Therapeutics Market Segment Insights

Antimicrobial Therapeutics Application Insights

The Market segments of Antimicrobial Therapeutics, based on application, includes antiviral, antibacterial, antifungal, and antiparasitic. The antiviral category had the most market share in 2022. The rising prevalence of viral infections including the flu, hepatitis, COVID-19, and HIV/AIDS is what's fueling the segment's expansion. Additionally, the emergence of pandemic illnesses like COVID-19 enhanced the need for antiviral medications because remdesivir was one of the compounds being studied for the treatment of COVID-19. As a result, the global outbreak of viral diseases is expected to contribute to market growth during the forecast period.

Antimicrobial Therapeutics End User Insights

The Antimicrobial Therapeutics Market segmentation, based on end user, includes pharmacies, hospitals and clinics, research and academic institutes. In 2022, the pharmacies category had a larger market share. The market for antibacterial medications is expanding significantly, but commercial prospects are being further hampered by the relatively small drug pipeline. However, it is anticipated that the development of branded medications would increase as a result of the diligent efforts made by the governments of many nations, particularly in Europe and North America. For instance, the U.S. Food and Drug Administration announced in February 2021 the formation of the Antibacterial Drug Development Task Force at the Center for Drug Evaluation and Research (CDER) to aid in the discovery of new antibacterial medications. In the future, pharmacies will also function as a full-fledged distribution channel, enabling same-day or next-day delivery and supporting the validity of prescriptions. According to recent World Health Organization research, 1 in 10 medical items circulating in low- and middle-income nations are either subpar or fake.

Figure 1: Antimicrobial Therapeutics Market, by End User, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Antimicrobial Therapeutics Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Antimicrobial Therapeutics Market dominated this market in 2022 (45.80%). These markets have a strong regulatory framework and an advanced healthcare infrastructure. One of the main reasons propelling the North American market is the increase in infectious diseases and rising government healthcare spending. The U.S. government is adopting a number of actions, such as boosting R&D activities for novel medicines to manage infectious diseases and undertaking antibiotic stewardship initiatives. Further, the U.S. market of antimicrobial therapeutics held the largest market share, and the Canada market of antimicrobial therapeutics was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: ANTIMICROBIAL THERAPEUTICS MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Antimicrobial Therapeutics market accounts for the significant market share. The primary factors influencing the demand for these medications in the European market are the quick growth of the healthcare infrastructure in a number of European nations, the rising investment in research and development activities, and the expanding number of hospitals in the region. Further, the German market of antimicrobial therapeutics held the largest market share, and the U.K market of antimicrobial therapeutics was the fastest growing market in the European region

The Asia Pacific Antimicrobial Therapeutics market, is expected to register fastest growth from 2023 to 2032. The increased usage of antibiotics, rise in the occurrence of infectious diseases, and rise in government initiatives to create novel medicines to treat infections with drug resistance can all be attributable to this. Additionally, the existence of generic competitors helps the regional market expand. The largest markets in the region for antibiotics are India and China. The main drivers of market expansion in these countries are unrestricted sales and excessive antibiotic use. Moreover, China’s market of antimicrobial therapeutics held the largest market share, and the Indian market of antimicrobial therapeutics was the fastest growing market in the Asia-Pacific region.

Antimicrobial Therapeutics Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Antimicrobial Therapeutics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Antimicrobial Therapeutics industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Antimicrobial Therapeutics industry to benefit clients and increase the market sector. In recent years, the Antimicrobial Therapeutics industry has offered some of the most significant advantages to medicine. Major players in the Antimicrobial Therapeutics market, including AbbVie Inc., Astellas Pharma Inc., Bavarian Nordic AS, Biocidium Biopharmaceuticals Inc., Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., CSL Ltd., Emergent BioSolutions Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Inovio, Pharmaceuticals Inc., Johnson and Johnson Services Inc., Merck and Co. Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Novavax Inc., Pfizer Inc., Sanofi SA, and Wockhardt Ltd., are attempting to increase market demand by investing in research and development operations.

Sandoz Inc, a division of Novartis AG, is a global generic pharmaceutical company involved in the development, manufacturing, distribution, and sale of a wide range of prescription medicines, protein products, and biosimilars. Additionally, Sandoz offers intermediary products like active pharmaceutical ingredients (APIs) and biotechnology manufacturing services to other companies. The company supplies active ingredients and finished dosage forms for various therapeutic areas, including dermatology, cancer, cardiovascular, respiratory, metabolism, central nervous system, pain management, ophthalmic, gastrointestinal, and hormonal therapies. Sandoz distributes its products to wholesalers, pharmacies, hospitals, and other healthcare facilities. Headquartered in Princeton, New Jersey, USA, Sandoz has further strengthened its position in the global market by acquiring GSK's cephalosporin business in February 2021.

Pfizer Inc is a biopharmaceutical company involved in the discovery, development, manufacturing, and commercialization of healthcare products. Pfizer's product portfolio encompasses treatments for various conditions, including cardiovascular diseases, metabolic disorders, pain management, women's health, cancer, inflammation, immune disorders, and rare diseases. The company also offers sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs), and contract manufacturing services. In July 2019, Pfizer entered into a definitive agreement with Mylan, resulting in the establishment of a new company named Viatris. This merger has enabled Pfizer to expand its global presence.

Key Companies in the market of antimicrobial therapeutics include

• AbbVie Inc.


• Astellas Pharma Inc.


• Bavarian Nordic AS


• Biocidium Biopharmaceuticals Inc.


• Bristol Myers Squibb Co.


• Cadila Pharmaceuticals Ltd.


• CSL Ltd.


• Emergent BioSolutions Inc.


• Hoffmann La Roche Ltd.


• Gilead Sciences Inc.


• GlaxoSmithKline Plc


• Inovio Pharmaceuticals Inc.


• Johnson and Johnson Services Inc.


• Merck and Co. Inc.


• Mitsubishi Tanabe Pharma Corp.


• Novartis AG


• Novavax Inc.


• Pfizer Inc.


• Sanofi SA


• Wockhardt Ltd.

Antimicrobial Therapeutics Industry Developments

September 2021 The U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREER (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the treatment of moderate to severe pain brought on by endometriosis, according to a statement from Myovant Sciences and Pfizer Inc.

July 2021 In order to conduct research, develop, and market small molecule medicines aimed against the GPR75 target with the potential to treat obesity and associated co-morbidities, AstraZeneca announced that it had partnered with Regeneron.

Antimicrobial Therapeutics Market Segmentation

Antimicrobial Therapeutics Application Outlook

• Antiviral


• Antibacterial


• Antifungal


• Antiparasitic

Antimicrobial Therapeutics End User Outlook

• Pharmacies


• Hospitals and Clinics


• Research and Academic Institutes

Antimicrobial Therapeutics Regional Outlook

• 
  

  North America

  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  

  Europe

  
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  

  Asia-Pacific

  
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America